In the most recent session, Schlumberger N.V. (NYSE:SLB) shares have traded -0.01%. Following the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent review, the stock has been noted $-1.96 away from the 50-day moving average of $79.79 and $-3.51 away from the 200-day moving average of $81.34. From a different angle, the stock has been recently recorded -11.40% off of the 52-week high of 87.84 and +9.10% removed from the 52-week low of 71.34.
Currently, Schlumberger N.V. Common Stock has a price to earnings ratio of N/A. Analysts and investors may also opt to evaluate a company's PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. If a company has a PEG Ratio below one, it may be viewed as undervalued. If a company has a PEG Ratio above one, it may show that the company is overvalued. A PEG Ratio near one may be viewed as fair value. The stock currently has a PEG Ratio of -54.60.
Price Target Update
Analysts polled by Thomson Reuters have set a consensus target price of $96.75 on shares. Target prices may vary from one analyst to another due to the various ways they may proceed to calculate future price targets. This is a near-term estimation for the next 12-18 months.
Research analysts covering Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) are projecting that the shares reach $427.214 within the next 12-18 months. This is the consensus number derived from the 14 analyst reports taken into consideration. The most bullish, or aggressive analyst target pins the projected price at $598, while the most bearish, or conservative analyst sees the stock reaching $350.
Broker Rating Update on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Zacks provides analysts with an Average Broker Rating (or ABR), basing it on sell-side recommendations. Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) currently have an ABR of 2.22. This is based on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell. Moving to earnings estimates, for this current fiscal period, Wall Street analysts have projected that the company will post $2.5 earnings per share. This is the current Zacks consensus EPS which was calculated at the time of writing. Analysts will likely revise their estimates leading in to the actual results date.
taking a look at the most recent period, which closed on 2016-12-31, Regeneron Pharmaceuticals, Inc. reported EPS of $2.19 for a surprise factor of -12.75%, calculated by being $-0.32 away from analyst projections.
Investors will be marking their calendars for 2017-05-04, when the company is planning to release their quarterly results.